These alterations include changes in the MGMT promoter methylation status for glioblastoma [1], IDH1/2 mutation, TERT promoter mutation and 1p/19q co-deletion for WHO grade 2 and 3 gliomas [2,3], and they have had a major impact on both standard treatment of care and on the design of randomized clinical trials for this malignant disease [4]. This evidence concerns the gene IDH1 and central nervous system cancer.